<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2557">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04382131</url>
  </required_header>
  <id_info>
    <org_study_id>AC20042</org_study_id>
    <nct_id>NCT04382131</nct_id>
  </id_info>
  <brief_title>Hypertonic Saline Nasal Irrigation and Gargling in Suspected or Confirmed COVID-19 (ELVIS COVID-19)</brief_title>
  <official_title>Hypertonic Saline Nasal Irrigation and Gargling for Suspected or Confirmed COVID-19: Pragmatic Web-based Bayesian Adaptive Randomised Controlled Trial (ELVIS COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Edinburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ELVIS COVID-19 is a pragmatic web-based Bayesian adaptive randomised controlled, parallel
      group trial of hypertonic saline nasal irrigation and gargling (HSNIG) compared to standard
      care in participants with clinically suspected or confirmed COVID-19 being managed at home.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      COVID-19, a recently identified disease, has spread worldwide rapidly and is now a pandemic.
      There is no cure for it yet. Though it causes mild to moderate illness in most people, it can
      cause serious illness and death, particularly in the elderly, those with chronic illness or a
      weakened immune system.

      The ELVIS COVID-19 study is to find out if nasal washout (i.e. irrigation) and gargling with
      salt water (hypertonic saline) helps individuals with COVID-19 get better faster. Preliminary
      data from those with the common cold has found that nasal washouts and gargling with salty
      water may be helpful in reducing the length of the illness. This trial will help us find out
      if the same treatment is helpful in improving COVID-19 symptoms and preventing the spread of
      the disease.

      After self-consenting online, participants will be randomised into one of two study groups.
      The control group will be given standard personal, household hygiene and social distancing
      advice. The intervention group will be taught using online videos how to prepare and perform
      hypertonic saline nasal irrigation and gargling (HSNIG) up to 12 times daily in addition to
      standard advice.

      Participants in both the intervention and control groups will complete an online daily diary
      first thing in the morning, which will be sent to them via an email link. The diaries will be
      completed every day until the participant reports they are well or for a maximum of 14 days
      or participant withdrawal.This study will look for participants across Scotland, who are 18
      years old or older and who are self-isolating with confirmed or suspected COVID-19, with
      symptoms that have developed no more than 48 hours before consent to the study. The study is
      conducted online and everything we ask participants to do will be done at home with items
      they will already have.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 23, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>ELVIS COVID-19 is a pragmatic web-based Bayesian adaptive randomised controlled, parallel group trial of hypertonic saline nasal irrigation and gargling (HSNIG) compared to standard care in participants with clinically suspected or confirmed COVID-19 being managed at home. Participants from Scotland will be self-recruiting via web based system which will randomise in a 1:1 ratio to perform HSNIG or not.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to resolution of symptoms as defined by the single question 'how unwell do you feel today'.</measure>
    <time_frame>Maximum of 14 days</time_frame>
    <description>Time until participant reports well</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of all symptoms</measure>
    <time_frame>1-14 days or until the participant reports that they are well</time_frame>
    <description>Recorded using validated Wisconsin Upper Respiratory Symptom Survey-24 (WURSS-24) questionnaire and daily diaries. The WURSS-24 questionnaire assesses the interference on daily life and severity of symptoms on a scale of 1 (not at all) to 7 (severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The length of time for individual symptoms to resolve</measure>
    <time_frame>1-14 days or until the participant reports that they are well</time_frame>
    <description>Recorded using validated Wisconsin Upper Respiratory Symptom Survey-24 (WURSS-24) questionnaire and daily diaries. The WURSS-24 questionnaire assesses the interference on daily life and severity of symptoms on a scale of 1 (not at all) to 7 (severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of individual symptoms</measure>
    <time_frame>1-14 days or until the participant reports that they are well</time_frame>
    <description>Recorded using validated Wisconsin Upper Respiratory Symptom Survey-24 (WURSS-24) questionnaire and daily diaries. The WURSS-24 questionnaire assesses the interference on daily life and severity of symptoms on a scale of 1 (not at all) to 7 (severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contacting healthcare (NHS 24, OOH, GP)</measure>
    <time_frame>1-14 days or until the participant reports that they are well</time_frame>
    <description>Number of participants and frequency of contacts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants needing GP appointments</measure>
    <time_frame>1-14 days or until the participant reports that they are well</time_frame>
    <description>Number of participants and frequency of contacts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants attending hospital</measure>
    <time_frame>1-14 days or until the participant reports that they are well</time_frame>
    <description>Number of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in hospital if admitted</measure>
    <time_frame>1-14 days or until the participant reports that they are well</time_frame>
    <description>Number of days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants reporting over the counter medication use</measure>
    <time_frame>1-14 days or until the participant reports that they are well</time_frame>
    <description>Number of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in transmission to household contacts</measure>
    <time_frame>1-14 days or until the participant reports that they are well</time_frame>
    <description>Number of people within participant's household who develop symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants reporting side effects of nasal irrigation</measure>
    <time_frame>1-14 days or until the participant reports that they are well</time_frame>
    <description>Number of participants in intervention arm reporting side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Types and severity of side effects reported</measure>
    <time_frame>1-14 days or until the participant reports that they are well</time_frame>
    <description>Participants asked if they have experienced common side effects or other and to rate the severity on a 7 point scale of 'Did not have this side effect' to 'severe'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of over the counter medication used</measure>
    <time_frame>1-14 days or until the participant reports that they are well</time_frame>
    <description>Estimated cost requested when participant states over the counter medication used</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">405</enrollment>
  <condition>Upper Respiratory Tract Infections</condition>
  <condition>Virus</condition>
  <condition>COVID</condition>
  <condition>Virus Shedding</condition>
  <condition>Virus Diseases</condition>
  <arm_group>
    <arm_group_label>Hypertonic saline nasal irrigation and gargling</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the intervention arm will be asked to perform hypertonic saline nasal irrigation and gargling up to 12 times daily for a maximum of 14 days or until they report that they feel well.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants in the control arm will be given standard NHS guidance for the management of their symptoms and household hygiene.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NaCl Solution</intervention_name>
    <description>NaCl Solution prepared by participants at home using water and salt</description>
    <arm_group_label>Hypertonic saline nasal irrigation and gargling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (â‰¥18 years)

          -  Those living within the UK

          -  Those self-isolating at home within 48 hours of the start of the illness with:

               1. Clinical symptoms suggestive of COVID-19 (i.e. those who have at least one of the
                  following symptoms: recent onset of (i) new continuous cough and/or (ii) high
                  temperature) and/or (iii) loss of, or change in, sense of smell or taste
                  (anosmia) OR

               2. Those with virologically confirmed SARS-CoV-2 infection and clinical symptoms
                  indicative of COVID-19 (as detailed in (a) above).

          -  Provision of informed consent

        Exclusion Criteria:

          -  Onset of illness&gt;48 hours

          -  Inability to consent

          -  Pregnancy

          -  Immunosuppression

          -  Inability to perform HSNIG

          -  Those taking part in another interventional medical trial

          -  Those without access to a supply of salt

          -  Those who have had a negative COVID-19 swab result for the present symptoms

          -  Those with suspected/confirmed COVID-19 in whom hospital admission is recommended

          -  Those who do not have access to email/internet

          -  Those living in a household with another person currently participating in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aziz Sheikh</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Edinburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aziz Sheikh</last_name>
    <phone>01316514151</phone>
    <email>aziz.sheikh@ed.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emma Ward</last_name>
    <phone>01316519910</phone>
    <email>ELVIS-COVID19@ed.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NHS Lothian</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenny Scott</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 8, 2020</study_first_submitted>
  <study_first_submitted_qc>May 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2020</study_first_posted>
  <last_update_submitted>September 1, 2020</last_update_submitted>
  <last_update_submitted_qc>September 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

